C83.3A
Diffuse large B-cell lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma, a cancer that originates in the lymphatic system. When this condition is successfully treated and no signs of the disease are present, it is considered to be in remission. The ICD-10 code C83.3A specifically refers to DLBCL that is in remission, indicating that the disease has responded well to treatment. Understanding this diagnosis involves learning about the disease's nature, causes, symptoms, diagnosis process, and typical treatment approaches.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting B lymphocytes Immune system dysfunction Infections such as Epstein-Barr virus (EBV) or Helicobacter pylori Environmental exposures to certain chemicals or pesticides Prior history of other cancers or treatments like chemotherapy and radiation
Key Symptoms: Swollen lymph nodes, often painless Unexplained weight loss Fever and night sweats Persistent fatigue Abdominal pain or swelling Breathlessness or cough if the chest is involved Loss of appetite
Diagnostic & Treatment
Diagnosis Path: The diagnosis of diffuse large B-cell lymphoma typically involves multiple steps, including: - Physical examination to check for swollen lymph nodes or other signs. - Imaging tests such as CT scans, PET scans, or MRI to identify affected areas. - A biopsy, where a tissue sample from the lymph node or other affected area is examined under a microscope. - Laboratory tests to assess blood cell counts and organ function. - Additional tests if necessary, such as bone marrow biopsies, to determine the extent of the disease. When the condition is in remission, it means that after treatment, these investigations have shown no active disease presence, although ongoing monitoring is often recommended.
Treatment Protocols: Treatment options for diffuse large B-cell lymphoma usually include chemotherapy, targeted therapy, immunotherapy, or a combination of these. Common approaches involve: - Chemotherapy regimens such as R-CHOP, which combine several drugs to kill cancer cells. - Targeted drugs that specifically attack cancer cell features. - Monoclonal antibodies like rituximab that boost the immune system's ability to fight the cancer. - In some cases, stem cell transplants may be considered after initial treatments. Once in remission, treatment focus shifts to monitoring for potential relapse, managing side effects, and maintaining overall health. Follow-up care involves regular medical visits and imaging tests. Patients who are in remission usually have a good prognosis, but ongoing observation is important for early detection of any recurrence.
Clinical Advice & FAQs
Billing Guidance
Is C83.3A a billable ICD-10 code?
Yes, C83.3A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.3A?
Clinical documentation must specify the nature of Diffuse large B-cell lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
